Navigation Links
Celtaxsys Begins US Enrollment for Phase 2 Trial of Acebilustat Anti-Inflammatory Therapy for Cystic Fibrosis
Date:10/8/2015

ATLANTA, Oct. 8, 2015 /PRNewswire/ -- Celtaxsys, a clinical stage drug development company focused on advancing care for patients suffering from orphan inflammatory diseases, announced today the commencement of the US arm of an international phase 2 clinical trial for its flagship compound, acebilustat, in patients with cystic fibrosis (CF). The study will be conducted at approximately 60 sites in the United States and European Union, with the EU sites anticipated to begin enrollment early 2016. This landmark clinical trial testing once-daily oral acebilustat treatment over 48 weeks could be the first to establish proof-of-concept for an anti-inflammatory treatment specifically designed to prevent long-term loss of lung function in CF patients. The study will test once daily oral doses of 50 mg and 100 mg acebilustat against placebo on top of background therapy in adult CF patients.

Acebilustat is a first-in-class neutrophil modulator that controls a key inflammatory signal overexpressed in CF and other orphan inflammatory diseases. Acebilustat has been granted orphan drug status for the treatment of CF in the US and the EU.  Results from initial clinical studies in CF patients demonstrated acebilustat's ability to moderate the over-activated inflammatory response in CF, decreasing neutrophils in the lung by 65% and decreasing damaging neutrophil elastase in just two weeks of treatment. Acebilustat did this without jeopardizing the patient's immune response to infection. Importantly, acebilustat treatment is applicable to all CF patients irrespective of their gene mutation and can be used on top of background therapy, including Kalydeco and Orkambi.

The Phase 2 CF trial was designed in conjunction with and supported by a grant from Cystic Fibrosis Foundation Therapies, Inc. (CFFT), the non-profit drug discovery and development affiliate of the Cystic Fibrosis Foundation. It will include approximately 30 sites in the US under the oversight of Principal Investigator Dr. Stephen Rowe MD MSPH, Professor at the University of Alabama Birmingham School of Medicine, Director of the Cystic Fibrosis Transition Clinic, and Director of the CFFT Development Network Center for CFTR Detection. Said Dr. Rowe, "CF patients are in desperate need of efficacious and safe anti-inflammatory therapies to control progressive lung disease.  Evaluation of the long term effects of acebilustat is a very important step in that direction, given the favorable Phase 1b results in CF patients."

For more information, please visit http://clinicaltrials.gov/show/NCT02443688.

Logo - http://photos.prnewswire.com/prnh/20150605/221207LOGO


'/>"/>
SOURCE Celtaxsys, Inc.
Copyright©2015 PR Newswire.
All rights reserved

Related medicine technology :

1. Celtaxsys, Inc. Gains FDA Clearance for Landmark Phase 2 Trial of Anti-Inflammatory Treatment for Cystic Fibrosis (CF)
2. Celtaxsys Has Regulatory Clearance to Begin Phase 2 Trial of Oral CTX-4430 Anti-Inflammatory Therapy for Moderate to Severe Acne Vulgaris - Recruitment of Patients to Commence Immediately
3. Celtaxsys Announces Sanjeev Ahuja as Chief Medical Officer
4. Greg Duncan Appointed President and Chief Executive Officer of Celtaxsys, Inc.
5. Celtaxsys Announces Successful Completion of Phase 1 Clinical Trial for Development of CTX-4430
6. Celtaxsys Restructures, Enhances Operational Focus
7. Construction Begins at Genovate Biotechnologys Insulin Ecological Industrial Park in Chinas Changzhou National Hi-tech District
8. NOWDiagnostics Inc. Begins Manufacturing New Point-of-Care Tests Capable of Providing Results in Just Minutes with the Same Reliability as Lab-Based Tests
9. Worlds Most Technologically Advanced Cannabis Cultivation Facility And Laboratory Begins Operating In Delavan, Illinois
10. GSK begins shipping 2015-16 US flu vaccines with focus on customer needs, volume, and speed
11. Aethlon Medical Begins Trading on the Nasdaq Capital Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2019)... , ... January 13, 2019 , ... Datalogic , ... to announce the Memor™ 10 rugged mobile computer , one of the few ... 10 is part of a new family of rugged Android PDA devices from Datalogic. ...
(Date:1/11/2019)... ... ... According to research, acupuncture can quickly and effectively treat sinusitis, allergy, and asthma symptoms, ... respiratory treatment they need at its Houston clinic. , “We don’t just treat the ... and Chinese Medicine can treat a wide range of conditions,” said Sylvia He, owner ...
(Date:1/11/2019)... PITTSBURGH (PRWEB) , ... January 11, 2019 , ... ... Magazine’s fastest-growing private companies and ranked among the top US security companies for ... to Work For winner. This award recognizes companies that excel at employee ...
Breaking Medicine Technology:
(Date:1/14/2019)... ... January 14, 2019 , ... Trees can be overweight too! ... should have trees pruned, and winter is a great time to clean things up ... can lead to serious damage, especially during windy or icy storms. The crown of ...
(Date:1/14/2019)... , ... January 14, 2019 , ... ... availability of the newly updated International Audit Protocol Consortium (IAPC) EHS audit protocol ... audit protocols to understand the scope of their EHS regulatory obligations and rapidly ...
(Date:1/13/2019)... SCOTCH PLAINS, N.J. (PRWEB) , ... January 12, 2019 , ... Top Docs is proud to present the following recently reviewed and approved providers for December 2018. , IL ... MEDICINE, Dr. Barbara Amsler , Dr. Naresh Chandan , ... , NEUROLOGY, Dr. Amarish Dave , OBGYN, ...
(Date:1/11/2019)... ... January 11, 2019 , ... The Captive Insurance Companies ... Captive Insurance Solutions for New Risk Challenges” essay contest for college risk management ... are: , Christian Ferrara and Charles Fisher, Appalachian ...
(Date:1/11/2019)... ... January 11, 2019 , ... Women’s Excellence specializes in ... tissue, relieve pain, and help restore fertility. , Endometriosis is a disease in ... typically grows on the ovaries, fallopian tubes, and the inner lining of the ...
Breaking Medicine News(10 mins):